Fixed dose subcutaneous low molecular weight heparin (LMWH) v adjusted dose unfractionated heparin (UFH) for acute venous thromboembolism*

OutcomesFollow upNumber of trials (n)Weighted event ratesRRR (95% CI)NNT (CI)
LMWHUFH
*Abbreviations defined in glossary; weighted event rates, RRR, NNT, and CI calculated from data in article using a fixed effect models.
Recurrent venous thrombo-embolismDuring treatment15 (6060)1.4%2.4%31% (2 to 51)100 (100 to ∞)
3 months13 (5831)3.0%5.0%30% (11 to 46)50 (34 to 100)
6 months6 (2781)3.7%5.7%31% (3 to 51)50 (34 to ∞)
3–6 months18 (8122)3.4%5.4%31% (15 to 44)50 (34 to 100)
Major haemorrhageDuring treatment19 (7124)1.0%2.0%42% (16 to 60)100 (100 to ∞)
All cause mortality3–6 months18 (8054)5.0%6.0%23% (7 to 36)100 (50 to ∞)